logo-loader

Open Orphan PLC targeting Q3 for profitability as it expands range of pharma and COVID-19 services

Published: 08:15 25 Jun 2020 EDT

Proactive Research analyst Emma Ulker says Open Orphan PLC's (LON:ORPH) full year 2019 results reflect a period of transition, as the company consolidated only six months of Venn revenues, with the focus being on integration and ongoing streamlining of the business, following the post–period acquisition of hVIVO in January.

Ulker says the outlook includes expanding its range of pharma services and completing the development of a COVID-19 HVC model which is already attracting the attention of the global pharma industry.

Click here to read Emma Ulker's latest update Open Orphan: Focused on a buoyant outlook

Poolbeg Pharma chair discusses shift to executive role; hVIVO share sale

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss his new hands-on role at the company. Stepping up as the executive chairman at Poolbeg Pharma, Friel expressed his intention to replicate the success he achieved with hVIVO, another...

on 02/15/2024